24-Wk data from CONTEXT trial comparing GW433908/ritonavir QD & BID to Lopinavir/ritonavir BID

re subjects discontinued LPV/r due to AEs (6 percent) than 908/rQD or 908/r BID (both <1 percent).

Likewise, Grade 3-4 lab abnormalities were similar between all three treatment arms, and all regimens had minimal impact on plasma lipids. The incidence of Grade 3-4 lipid abnormalities was low. No subject experienced a Grade 3-4 elevation in cholesterol, whereas elevated triglyceride levels occurred in 8 percent of patients taking 908/r BID (n=8,) versus 4 percent of patients taking 908/r QD (n=4) or LPV/r BID (n=4). Mean fasting cholesterol levels for all three study groups remained below the recommended National Cholesterol Education Program (NCEP) intervention guidelines.

Study Demographics

The study population comprised patients enrolled from 103 centers in 13 countries worldwide. Approximately 16 percent of patients enrolled in CONTEXT are female, and the age range of all patients is 24 72 years (median 41 years). Sixty-seven percent of patients are Caucasian, 24 percent are of African descent and 9 percent are Hispanic. Criteria for entry into the study included treatment-experienced patients with current failure of antiretroviral therapy. To enroll in the CONTEXT trial, patients had to have a screening viral load >1,000 copies/mL and no active or acute Category C events (indicative of AIDS disease) according to guidelines established by the Centers for Disease Control and Prevention.

Summary of Clinical Trials with 908

More than 1,200 people have participated in three Phase III trials to test the safety and efficacy of 908: NEAT, SOLO and CONTEXT. The SOLO study was an open-label trial with 649 HIV+, treatment-nave patients. Participants were randomized to receive either 1400 mg of 908 plus 200 mg ritonavir (908/r) QD or 1250 mg of nelfinavir BID. All also received the two NRTIs, ABC and 3TC. The trial, conducted at more than 100 research centers worldwide, was designed to assess the safety and efficacy of each

Contact: Amy Kling
Public Communications Inc.

Page: 1 2 3 4

Related biology news :

1. Phase II trials of second-generation antisense cancer drug planned following successful early study
2. Innovative ceramic-on-metal hip replacements to undergo clinical trials
3. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
4. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
5. Pharmacogenomics could replace trial-and-error with science from the human genome
6. Wilex & Fox Chase Cancer Center begin trial w/ novel compound targeting tumor invasion & metastasis
7. Small trial shows daclizumab add-on therapy improves MS outcome
8. Tigecycline - antibiotic evaluated in surveillance trial
9. OneWorld Health completes enrollment, treatment in Phase III India trial
10. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
11. First large-scale trial of genetically personalised treatment for breast cancer to start soon

Post Your Comments:

(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):
(Date:7/22/2018)... WESTMINSTER, Colo. (PRWEB) , ... July 21, 2018 , ... ... recent research workshop on the off-target movement of dicamba herbicides is available on the ... research protocols that will help all stakeholders better understand and manage factors contributing to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
Breaking Biology Technology:
Cached News: